HomeCompareTRGNF vs EPRT

TRGNF vs EPRT: Dividend Comparison 2026

TRGNF yields 200.00% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRGNF wins by $119.30M in total portfolio value
10 years
TRGNF
TRGNF
● Live price
200.00%
Share price
$1.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$119.36M
Annual income
$60,176,096.29
Full TRGNF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — TRGNF vs EPRT

📍 TRGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRGNFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRGNF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRGNF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRGNF
Annual income on $10K today (after 15% tax)
$17,000.00/yr
After 10yr DRIP, annual income (after tax)
$51,149,681.85/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, TRGNF beats the other by $51,138,767.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRGNF + EPRT for your $10,000?

TRGNF: 50%EPRT: 50%
100% EPRT50/50100% TRGNF
Portfolio after 10yr
$59.71M
Annual income
$30,094,468.50/yr
Blended yield
50.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

TRGNF
No analyst data
Altman Z
2.5
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRGNF buys
0
EPRT buys
0
No recent congressional trades found for TRGNF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRGNFEPRT
Forward yield200.00%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$119.36M$63.4K
Annual income after 10y$60,176,096.29$12,840.73
Total dividends collected$112.49M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: TRGNF vs EPRT ($10,000, DRIP)

YearTRGNF PortfolioTRGNF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$30,700$20,000.00$11,205$505.18+$19.5KTRGNF
2$90,232$57,383.18$12,672$682.46+$77.6KTRGNF
3$254,173$157,624.56$14,490$930.48+$239.7KTRGNF
4$686,927$414,961.74$16,786$1,282.69+$670.1KTRGNF
5$1,783,118$1,048,106.39$19,753$1,791.56+$1.76MTRGNF
6$4,450,613$2,542,677.12$23,677$2,541.64+$4.43MTRGNF
7$10,693,420$5,931,263.38$29,008$3,672.99+$10.66MTRGNF
8$24,760,608$13,318,648.86$36,463$5,425.08+$24.72MTRGNF
9$55,315,649$28,821,798.66$47,238$8,221.57+$55.27MTRGNF
10$119,363,841$60,176,096.29$63,385$12,840.73+$119.30MTRGNF

TRGNF vs EPRT: Complete Analysis 2026

TRGNFStock

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Full TRGNF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this TRGNF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRGNF vs SCHDTRGNF vs JEPITRGNF vs OTRGNF vs KOTRGNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.